Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 4 1Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 63Lymphoma, Large B-Cell, Diffuse 60Lymphoma 57Lymphoma, Non-Hodgkin 54Lymphoma, Follicular 43Lymphoma, Mantle-Cell 31Lymphoma, B-Cell, Marginal Zone 26Lymphoma, B-Cell 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Leukemia 19Burkitt Lymphoma 19Waldenstrom Macroglobulinemia 16Recurrence 16Hodgkin Disease 13Multiple Myeloma 9Lymphoma, Large-Cell, Immunoblastic 9Hematologic Neoplasms 8Leukemia, Myeloid, Acute 7Neoplasms, Plasma Cell 6Neoplasms 6Myelodysplastic Syndromes 6Leukemia, Prolymphocytic 6Lymphoma, T-Cell 5Intraocular Lymphoma 5Leukemia, Hairy Cell 4Neoplasm Metastasis 3Myeloproliferative Disorders 3Lymphoma, T-Cell, Peripheral 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, B-Cell 3

Interventions

ibrutinib 3Rituximab 3Lenalidomide 3spebrutinib 2fludarabine phosphate 2Cyclophosphamide 2tirabrutinib 1ricolinostat 1pembrolizumab 1ofatumumab 1navitoclax 1idelalisib 1fludarabine 1dinaciclib 1blinatumomab 1Rabeprazole 1Magnetic Resonance Imaging 1MLN 8237 1Leukapheresis 1KW-2478 1Itraconazole 1Immunotherapy, Adoptive 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Ciclopirox 1Blood Component Removal 1Biological Products 1Bendamustine Hydrochloride 1Antiemetics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, B-Cell × Rituximab × Clear all
NCT00788684 2025-02-20

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

AbbVie

Phase 1 Completed
29 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Hematologic Neoplasms

NCT01400685 2018-01-25

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Massachusetts General Hospital

Phase 1 Completed
34 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01744626 2016-04-19

Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Celgene Corporation

Phase 1 Completed
40 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡